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Abstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over 
human insulin have contributed to the widespread prescription of the premix, biphasic insulin 
aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews 
the available literature on the pharmacology, efficacy and safety of BIAsp 30 in T1DM and 
T2DM from an online search of the PubMed database. Following injection, BIAsp 30 reaches 
higher plasma insulin levels more quickly than human premix or basal insulin, giving effective 
reduction of postprandial hyperglycemia. In T1DM patients, randomized controlled trials 
(RCTs) have shown that HbA1c reduction is similar, but postprandial glycemic control is better, 
with BIAsp 30 than with human insulin regimens. In T2DM patients, lowering of HbA1c and 
postprandial hyperglycemia with BIAsp 30 compare favorably with optimized oral antidiabetes 
drug treatment, insulin glargine, and, in obese patients, human premix. An increase in minor 
hypoglycemia with BIAsp 30 relative to basal insulin has been reported in T2DM patients, 
but major and nocturnal hypoglycemia rates are generally low. Findings from RCTs in T2DM 
patients are supported by large observational studies. In summary, BIAsp 30 once to three times 
daily represents a simple and effective tool for the modern management of diabetes.
Keywords: biphasic insulin aspart, BIAsp 30, premix, type 1 diabetes, type 2 diabetes
Introduction
Diabetes mellitus is a global problem and the number of people being diagnosed 
is increasing rapidly. In 2000, the global prevalence of diabetes (type 1 and type 2 
combined – epidemiological reports do not generally distinguish between them) was 
estimated to be 2.8% – a total of 171 million people, which is forecast to more than 
double by 2030, to 366 million.1 This growth in diabetes is fuelled by increasing obesity, 
associated with high-calorie diets in developed countries and the modern sedentary 
lifestyle. The growing population is also a factor, with the largest change predicted 
to occur in the over 65 years age group.1 Since the prevalence of type 2 diabetes – the 
most frequently occurring type – increases with age, increase of the older population 
represents a major challenge for diabetes care in the future. The burden arises not just 
from the need to treat symptoms, but also the complications associated with hyper-
glycemia.2–4 The cost to society is therefore enormous.5,6
Given the extent of the problem, it is more important than ever that treatment of 
diabetes is as effective as possible. Recent baseline observational data from several 
countries/regions has shown that glycemic control in the type 2 diabetes popula-
tion is generally poor, with mean glycated hemoglobin A1c (HbA1c) levels of 9% or 
higher.7 This illustrates the need for treatment to be target-driven so that patients do Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 62
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not spend extended periods of time with hyperglycemia. 
Diabetes therapy should be intensified early and persistently, 
to keep pace with the progression of the disease.8 Adding 
insulin to the treatment regimen early is a key factor in good 
diabetes management since insulin is the most effective 
agent at reducing glycemia and doses can be titrated to 
target.9 Indeed, the International Diabetes Federation guide-
lines recommend adding insulin if HbA1c  7.5%.9 Timely 
intensification of insulin therapy should then follow. The 
potential benefits for complications are clear. The UKPDS 
study demonstrated that every 1% reduction in HbA1c was 
associated with a 21% reduction in risk for any diabetes-
related endpoint.10
The pathophysiology of type 1 diabetes is different to 
that of type 2, so insulin needs after diagnosis are different. 
Patients with type 1 diabetes usually have little or no endog-
enous insulin capacity remaining – the result of autoimmune 
destruction of the pancreatic beta-cells.11 Patients therefore 
require immediate and often complete insulin replacement. 
Among the treatment options are continuous subcutaneous 
insulin infusion (CSII) and multiple daily injections (MDI).12 
Although CSII is regarded as the ‘gold standard’ in insulin 
replacement in type 1 diabetes,13,14 MDI is the most common 
method of insulin delivery, which may comprise four or five 
daily injections of separate basal and prandial insulin, usually 
referred to as basal-bolus therapy.
Patients with type 2 diabetes have different insulin 
needs initially from those with type 1 diabetes, due to 
different etiology. Here, insulin resistance – often linked 
to obesity – puts undue stress on the insulin-producing 
beta-cells, which eventually are unable to produce enough 
insulin to maintain normo-glycemia.15 The resulting glucose 
toxicity causes the death of beta-cells, thus reducing overall 
insulin-producing capacity.16,17 At the point of diagnosis, 
patients typically have about 50% of their insulin-producing 
capacity remaining.18,19
Initial treatment steps are therefore somewhat different 
to those for type 1 diabetes. After the failure of lifestyle 
changes,20 an oral antidiabetes drug (OAD) is usually the 
first-line therapy, but the benefits may be relatively short-
lived. The UKPDS study found that three in four patients with 
type 2 diabetes were unable to maintain glycemic control with 
monotherapy 9 years after diagnosis.21,22 Initiating insulin 
therapy is the solution for many patients. In the advanced 
stages of type 2 diabetes when there is little or no endogenous 
insulin production, treatment requirements are essentially 
the same as those for patients with type 1 diabetes, that is, 
complete insulin replacement.
Insulin therapy may be initiated with basal insulin only, 
prandial (bolus) insulin only, or a premixed insulin compris-
ing both prandial and basal components in each injection 
(a basal-bolus regimen of four or five daily injections would 
usually be deemed too intensive for most patients starting 
insulin therapy). Each has their advantages and disadvantages: 
basal-only insulin does not provide for mealtime requirements 
and bolus insulin does not provide for fasting insulin require-
ments. The premixed insulins offer a good alternative as they 
address both fasting and postprandial glycemia.23
Over the last decade or so, insulin therapy has been 
revolutionized by the development of insulin analogs. These 
are chemically modified versions of human insulin which, via 
recombinant DNA technology, have changes in the amino acid 
sequence which give them more physiological pharmacokinetics 
when absorbed from a subcutaneous depot, compared with 
injected human insulin. There are rapid-acting analogs to 
control postprandial glycemia: insulin aspart (NovoRapid®; 
Novo Nordisk A/S, Denmark), insulin lispro (Humalog®; Eli 
Lilly, USA) and insulin glulisine (Apidra®; Sanofi-Aventis, 
France); and basal analogs for fasting glycemia: insulin detemir 
(Levemir®; Novo Nordisk A/S, Denmark) and insulin glargine 
(Lantus®; Sanofi-Aventis, France).
Insulin aspart has been incorporated into a premix 
formulation: biphasic insulin aspart 30/70 (BIAsp 30), 
comprising 30% rapid-acting, soluble, aspart for prandial 
coverage and 70% intermediate-acting, protaminated aspart, 
for basal coverage. The pharmacokinetics of aspart alone24,25 
are retained when incorporated into the premix.26 BIAsp 30 
can be injected from once (od) to three times (tid) daily in 
patients with type 2 diabetes, depending on their require-
ments, and tid in patients with type 1 diabetes. BIAsp 30 tid 
thus represents an alternative to basal-bolus therapy with 
fewer daily injections.
Because of these advantages, BIAsp 30 has become a 
widespread and commonly-prescribed treatment for patients 
with diabetes. The aim of this article is to review the use 
of BIAsp 30 in the treatment of type 1 and type 2 diabetes 
by examining the available literature. In so doing, I will 
compare its pharmacology, efficacy and safety profile with 
that of other insulins and establish the role of BIAsp 30 in 
diabetes management.
Methods
A literature search was carried out in January 2009 using the 
online database PubMed (www.pubmed.com/), for articles 
on the clinical use of BIAsp 30 using combinations of the 
following search terms: ‘aspart,’ ‘biphasic insulin aspart,’ Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 63
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‘BIAsp,’ ‘pathophysiology,’ ‘pharmacokinetics,’ ‘pharma-
codynamics,’ ‘type 1 diabetes’ and ‘type 2 diabetes’ among 
others. The articles identified were then screened for content 
and relevance.
BIAsp 30 pharmacology
The improved pharmacology of BIAsp 30 compared with 
human insulin and basal analog insulin has been the key to its 
success as a therapy for type 1 and type 2 diabetes. When com-
pared with human premix (biphasic human insulin 30/70 or 
BHI 30) in a single-injection study involving 24 healthy male 
volunteers, BIAsp 30 was found to reach 80% higher peak 
serum insulin levels (23.4 ± 5.3 vs 15.5 ± 3.7 mU/L, p  0.0001) 
in approximately half of the time (median [range]: 60 [45–70] 
vs 110 [90–180] minutes, p = 0.0001), following a subcutane-
ous injection of 0.2 U/kg body weight (Figure 1).27 Thus, over 
the first 90 minutes postinjection, the area-under-the insulin/
time curve (AUC 0–90 min) – a measure of bioavailability – 
was significantly higher for BIAsp 30 compared with BHI 30 
(estimated ratio 1.85, p  0.0001).
The pharmacodynamics (PD), or glucose-lowering 
effects, of the premixes reflected the pharmacokinetics (PK). 
The more rapid absorption of BIAsp 30 compared with BHI 
30 resulted in a greater and more rapid reduction in serum 
glucose. Over the first 6 hours postinjection, the lowest 
serum glucose measured was 3.2 ± 0.5 and 3.7 ± 0.5 mmol/L, 
respectively (p  0.0001), reached in 70 (range 70–80) and 
180 (100–300) minutes, respectively (p = 0.0001).
These differences between BIAsp 30 and BHI 30 have 
also been noted in patients with type 2 diabetes.28,29 In one 
crossover study, 24-hour PK and PD profiles were recorded 
after patients had received BIAsp 30 twice daily (bid) for 
2 weeks, and again after receiving BHI 30 for a further 2 
weeks.28
After each treatment period, maximum serum insulin 
levels and AUCinsulin 0 to 2 hours after breakfast and dinner 
were significantly higher with BIAsp 30 than with BHI 30 
(both p  0.05), with a shorter time to maximum level. 
Furthermore, serum glucose excursions were significantly 
lower after breakfast and dinner with the BIAsp 30 regimen 
(breakfast: 14.0 ± 5.5 vs 23.6 ± 5.5 mmol⋅L-1⋅h-1, p  0.05; 
dinner: 9.1 ± 5.9 vs 13.0 ± 6.4 mmol⋅L-1⋅h-1, p  0.05), 
although significantly higher after lunch compared with BHI 
30 (25.4 ± 11 vs 16.9 ± 8.5 mmol⋅L-1⋅h-1, p  0.05).28 No 
doubt this is due to the soluble human insulin having a longer 
duration of action than insulin aspart following the breakfast 
injection, so there was more carry-over of metabolic effect 
at lunchtime with BHI 30.
It is not surprising that pharmacological advantages 
have also been demonstrated over the basal insulin analog, 
insulin glargine, since this insulin does not have a prandial, 
rapid-acting component. In the crossover glucose-clamp 
study by Luzio et al30 12 insulin-naive patients with type 2 
diabetes received two injections of BIAsp 30 (0.25 U/kg at 
08.30 hours and 0.25 U/kg at 20.30 hours) on one day, and 
a single injection of glargine (0.5 U/kg at 08.30 hours) on 
another (the total daily insulin dose was therefore the same 
for the two treatments). Plasma glucose was clamped at a set 
level, and plasma insulin and glucose infusion rate (GIR – the 
amount of glucose needed to maintain the clamp level fol-
lowing the insulin injections) were measured for 24 hours. 
Maximum insulin concentration (Cmax) was higher for BIAsp 
30 than for glargine, due to the rapidly-absorbed aspart peaks 
following injection, as expected, and interestingly the insulin 
AUC 0–24 hour was 28% larger for BIAsp 30 (p = 0.001), 
demonstrating greater bioavailability at the same total daily 
dose. Consequently, the GIR AUC 0–24 hours was 35% 
higher for BIAsp 30 than for glargine, indicating greater 
glucose-lowering power dose-for-dose.30
Efficacy of BIAsp 30
Type 1 diabetes
Glycated hemoglobin A1c (HbA1c)
The use of BIAsp 30 in the type 1 diabetes patient population 
is not as common as it is in the type 2 population. This is 
partly because there are many more patients with type 2 
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Figure 1 Mean pharmacokinetic profiles (serum insulin) over 24 hours after subcutaneous 
injections of 0.2 U/kg biphasic insulin aspart 30/70 (BiAsp 30 – solid squares) or biphasic 
human insulin 30/70 (BHi 30 – solid circles) in healthy volunteers. reproduced with per-
mission from Jacobsen LV, Sogaard B and riis A. Pharmacokinetics and pharmacodynamics 
of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin 
Pharmacol. 2000;56:399–403.27 Copyright © Springer Science and Business Media.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 64
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diabetes, and partly because there is the need to provide 
complete insulin replacement in patients with type 1 diabetes, 
so pump therapy and basal-bolus – still widely regarded as 
the gold standard – are more popular than premix insulin 
analog therapy. Consequently, the number of studies of 
BIAsp 30 in people with type 1 diabetes is rather limited.31–33 
Comparing results from these trials is not straightforward 
because they employed different designs and comparators. 
However, some generalizations can be made. Three of these 
four studies measured the percentage of HbA1c (%HbA1c) to 
assess overall glycemic control and in all cases, no significant 
differences were found with respect to the comparator human 
insulin – either BHI 30 or soluble human insulin/NPH insulin. 
Specifically, in the 24-week crossover study by Chen et al32 
involving 23 type 1 patients, BIAsp 30 tid (before all main 
meals) was compared with basal-bolus therapy comprising 
soluble human insulin tid plus human NPH insulin at bedtime. 
NPH insulin was added at bedtime to the BIAsp 30 regimen 
for those patients who needed it. At the end of the study, 
HbA1c had dropped from 9.1% to 8.5% for both insulin regi-
mens (in the 12 patients who did not receive additional NPH 
insulin). These HbA1c values were significant improvements 
from baseline (p  0.05) for both regimens, achieved with 
the same total daily dose of 50 (I)U/day.
Results in young people have been more modest. In the 
16-week, parallel-group trial of 167 adolescents with type 
1 diabetes aged 10 to 17 years, BIAsp 30 tid was compared 
with BHI 30 at breakfast plus soluble human insulin at lunch 
and dinner.31 During the study, HbA1c was reduced from 
9.70 ± 1.52% at baseline to 9.39 ± 0.14% at final visit in the 
BIAsp 30 group, and from 9.55 ± 1.59% to 9.30 ± 0.15% in 
the human insulin group. Reductions were clearly very small 
and differences between treatments were not significant.
The last of these studies to report HbA1c is the 12-week 
parallel group trial of patients already using twice-daily 
insulin therapy 34 randomized to BIAsp 30 bid or BHI 30 
bid. Unfortunately, the results here are less clear-cut since 
patients with type 1 or type 2 diabetes were pooled for the 
efficacy analyses. Of the 291 patients exposed to therapy, 
104 (36%) had type 1 diabetes. From a baseline HbA1c of 
approximately 8.20% (8.37% for type 1 patients, 8.09% for 
type 2 patients), BIAsp therapy resulted in final values of 
8.14%. Similarly, from a baseline HbA1c of approximately 
8.25% (8.38% for type 1 patients, 8.18% for type 2 patients), 
BHI 30 therapy resulted in final values of 8.15%; this small 
treatment difference was not significant. Given the modest 
improvement in HbA1c, had type 1 and type 2 patients 
been analysed separately, it seems unlikely that a significant 
treatment difference would have been observed in patients 
with type 1 diabetes.34
Postprandial glycemic control
Another generalization about efficacy can be made from these 
trials in patients with type 1 diabetes: all report significant 
reductions in postprandial hyperglycemia with respect to 
comparator treatments.31–34 The study of 50 patients with 
type 1 diabetes (for a minimum of 2 years) by Hermansen 
et al involved a three-way crossover design.33 At each of 
three separate visits, patients received an injection of BIAsp 
30 immediately before a standard breakfast, or BHI 30 
immediately (t = 0) or 30 minutes before the meal (t = -30). 
Blood samples were then taken to measure 0- to 4-hour 
postprandial serum glucose levels (AUC 0–4 h). Treatment 
ratios for AUC 0 to 4 hour were in favor of BIAsp 30; BIAsp 
30/BHI 30 t = 0: 0.77, p  0.0001; BIAsp 30/BHI 30 t = -30: 
0.91, p  0.05.
Evidence from continuous therapy, however, may be 
more convincing. In the 24-week trial by Chen et al described 
above,32 which compared BIAsp 30 tid with basal-bolus 
therapy, mean (range) postprandial self-monitored blood 
glucose levels 2 hours after dinner were significantly lower 
with BIAsp 30 (8.3 [5.0–12.2] mmol/L) than with human insu-
lin tid plus NPH insulin at bedtime (9.6 [6.6–18.0] mmol/L); 
p  0.05 between treatments. Postprandial blood glucose 
levels after breakfast and lunch were not significantly 
different between treatments.32
Good reductions in postprandial glycemia can also be 
achieved with twice-daily BIAsp 30, as shown in the 12-week 
study by Boehm et al which as mentioned earlier, pooled 
type 1 and type 2 patients for the efficacy analyses.34 Here, 
BIAsp 30 bid resulted in a mean (SEM) prandial glucose 
increment of 1.66 (0.20) mmol/L, compared with 2.34 (0.19) 
mmol/L for BHI 30 bid (treatment difference [corrected for 
dose] was –0.69 mmol/L, p  0.01). These data represent the 
average for all three daily meals. When the meals are exam-
ined individually, it seems that treatment differences were seen 
after breakfast and dinner, but not after lunch, no doubt due to 
patients not receiving an insulin injection at lunchtime.
A similar pattern was observed in adolescent patients 
with type 1 diabetes.31 After 16 weeks of therapy with BIAsp 
30 tid or BHI 30 at breakfast plus human insulin at lunch 
and dinner, a lower mean (SEM) postprandial glucose incre-
ment was achieved with the BIAsp regimen (1.34 [3.45] at 
baseline to 0.37 [0.41] mmol/L at end-of-study), compared 
with the human insulin regimen (1.89 [3.26] at baseline to 
0.77 [0.44] mmol/L at end-of-study), p  0.05 between Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 65
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treatments (adjusted for baseline, country and last HbA1c 
value).31 Why these postprandial glucose improvements did 
not translate into greater reductions in HbA1c is not clear. It 
may be that the study was too short for the full potential in 
HbA1c reduction to be seen.
Type 2 diabetes
There are many more trials of BIAsp 30 in patients with type 
2 diabetes than in patients with type 1 diabetes, reflecting the 
difference in the size of the populations. This allows us to 
examine the studies according to patient population: studies 
of insulin-naive patients initiating insulin with BIAsp 30,35–48 
and studies of patients switching existing insulin therapy to, 
or intensifying with, BIAsp 30.44,49–51
Previously insulin-naive patients
For patients failing to maintain glycemic control on OAD 
therapy, BIAsp 30 represents a convenient and simple 
option for initiating insulin treatment, as it can be injected 
once-daily (od) in combination with OADs.40–42 Moreover, 
this regimen can effectively lower HbA1c and postprandial 
hyperglycemia when compared with an optimized regimen 
of OADs. In the 26-week trial by Bebakar et al,42 191 patients 
poorly controlled on one or two OADs were randomized to 
BIAsp 30 (0.2 U/kg/day) od before dinner in addition to their 
OADs, or to an optimized regimen of their existing OADs. 
At week 14, BIAsp 30 patients who had HbA1c  8.5% or 
fasting plasma glucose (FPG)  7 mmol/L added a further 
BIAsp 30 injection – at breakfast. At the end of the trial, 
reduction in HbA1c was greatest in the BIAsp 30 bid group, 
followed by BIAsp 30 od and OADs only (-1.34%, -1.24% 
and -0.67%, respectively; p  0.05 for both BIAsp 30 
regimens vs OADs only). Because of differences in baseline 
HbA1c, corresponding percentages of patients achieving 
target HbA1c  7.0% were 24%, 46% and 29%, respectively 
(baseline HbA1c was lowest in those who received BIAsp 
30 od, followed by those on OADs only). Self-measured 
90-minute postbreakfast plasma glucose was also lowered by 
a significantly greater amount with BIAsp 30 bid relative to 
optimized OADs: –2.76 vs –0.92 mmol/L (p  0.05); simi-
larly, 90-minute postdinner plasma glucose was lower with 
BIAsp 30 od than with OADs only (-3.41 vs -1.62 mmol/L; 
p  0.05). There were no significant treatment differences 
after lunch.42
In a smaller study of 46 insulin-naive patients with type 2 
diabetes, the addition of BIAsp 30 od to an existing regimen 
of metformin or glimepiride, or both, resulted in all three 
patient groups reaching HbA1c  7.0% after 6 months.41 
The fact that the OAD placebo group (who received BIAsp 
30 od only) also achieved this target makes the results for 
BIAsp 30 even more impressive.
Given these data, one may expect trials of BIAsp 30 bid 
to be at least as efficacious as od when compared with OAD 
regimens. Of course, this is not the case for published trials, 
since patient populations are different and OAD regimens 
vary from trial to trial.37,46,48 One three-arm study compared 
BIAsp 30 bid monotherapy with BIAsp 30 bid plus met-
formin, and glibenclamide plus metformin, in 341 patients 
poorly controlled on metformin monotherapy.46 After 16 
weeks, reductions in HbA1c appeared similar for all three 
treatment groups: –1.6%, –1.7% and –1.7%, respectively 
(the difference between the BIAsp 30 regimens was statis-
tically – but not clinically – significant). Furthermore, the 
mean prandial increment (average of all three meals) was also 
similar for the BIAsp 30 bid regimens and the OAD regimen, 
although when examined individually, the lunchtime incre-
ment was lower in the glibenclamide plus metformin group 
(treatment difference: –1.12 mmol/L vs BIAsp monotherapy, 
p  0.001, and –0.70 mmol/L, p = 0.036, vs BIAsp 30 plus 
metformin).
Perhaps one reason that the BIAsp 30 regimens in the 
above trial did not perform better is that dose titration was not 
optimal. The BIAsp 30 doses were adjusted every 1 to 7 days 
by 2 to 4 U, towards target blood glucose values of 5 to 
8 mmol/L. In the recent ACTION study,37 titration of the 
BIAsp doses was much more aggressive. Here, 200 insulin-
naive patients treated with metformin plus pioglitazone dur-
ing an 8-week run-in period were randomized to continue on 
this regimen or add BIAsp 30 bid to it. BIAsp 30 doses were 
adjusted according to an algorithm, with dose changes rang-
ing from -3 U (if mean plasma glucose was 4.4 mmol/L) 
to +9 U (if mean plasma glucose was 10.0 mmol/L over 
the preceding 3 days). After 34 weeks of therapy, BIAsp 30 
plus OADs resulted in a significantly larger HbA1c reduc-
tion than did metformin plus pioglitazone: -1.5% ± 1.1% vs 
0.2% ± 0.9% (p  0.0001). Not only did more patients reach 
HbA1c  7.0% with BIAsp 30 plus OADs (76% vs 24%), 
but the mean daily blood glucose profile was significantly 
lower at all eight time points with BIAsp 30/OADs compared 
with metformin plus pioglitazone.37 Clearly, compared with 
optimizing OADs, BIAsp 30 bid combination therapy can be 
an efficacious treatment strategy, particularly when titrated 
appropriately.
Commonly prescribed insulins for initiating insulin 
therapy in patients with type 2 diabetes include basal 
analogs, such as insulin glargine and detemir, and human Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 66
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premixed insulin – BHI 30. How BIAsp 30 compares with 
these insulins is therefore of interest. Comparative trials of 
insulin glargine od and BIAsp 30 bid have shown excellent 
reductions in HbA1c over 6 months, ranging from –1.6% 
to 2.79% for BIAsp 30 and -1.1% to -2.46% for insulin 
glargine.35,38 In the INITIATE study,35 BIAsp 30 bid plus 
metformin, produced a greater reduction in HbA1c after 
28 weeks than did insulin glargine od – both treatments 
with or without a thiazolidinedione (TZD): -2.79% ± 0.11% 
vs -2.36% ± 0.11% (p  0.01). This corresponded to 66% 
and 40% of patients reaching target HbA1c  7.0%, respec-
tively (p  0.001). Both insulins lowered the mean daily 
8-point blood glucose profile, but the profile with BIAsp 
30 was significantly lower at four time points (Figure 2). 
Only fasting glucose levels before breakfast were lower 
with insulin glargine.35
Interestingly, in a follow-up analysis of a subgroup of 
patients who did not receive a TZD in this study (at the time 
of this study TZDs were contraindicated with insulin in the 
EU,52) results were very similar,36 suggesting that insulin 
sensitizers do not increase the efficacy of BIAsp 30 plus 
metformin in this patient population.
There are very few studies comparing the efficacy of 
BIAsp 30 with BHI 30 in previously insulin-naive patients 
so generalizations cannot be made.39,40 In one of these 
involving 140 patients failing on metformin with or without a 
sulfonylurea or repaglinide, BIAsp 30 od plus metformin was 
trialled against BHI 30 od plus metformin, or NPH insulin 
plus metformin.40 HbA1c reductions after 12 weeks’ therapy 
were similar between all three groups: -1.3%, -1.1% and 
-1.2%, respectively, as were daily 8-point blood glucose 
profiles. However, in a Serbian study of obese patients with 
type 2 diabetes, the same treatment period yielded signifi-
cantly larger HbA1c reductions for BIAsp 30 than for BHI 30: 
-2.50% vs -1.18% (p 0.05, Figure 3).39 Furthermore, 65% 
of patients reached HbA1c  7.0% (the ADA recommended 
target53) with BIAsp 30 compared with 30% with BHI 30, 
and all time points on the 8-point daily blood glucose profile 
were lower.39 This was achieved with a slightly lower mean 
daily insulin dose for those on BIAsp 30 compared with those 
on BHI 30: 0.56 U/kg vs 0.58 U/kg, respectively.
Previously insulin-treated patients
The above data compare favorably with those from studies 
in previously insulin-treated patients who transferred to 
BIAsp 30.49,51 In these studies, which did not focus on obese 
individuals, no differences in HbA1c were found between 
BIAsp 30 and BHI 30, even after 2 years of therapy.49
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Figure 2 Daily 8-point mean blood glucose profiles after 28 weeks of treatment with BIAsp 30 bid or insulin glargine od (both in combination with metformin, with or without 
thiazolidinediones). Data from the iNiTiATe study. *p  0.05; errors are 2 Se. reproduced with permission from raskin P,   Allen e, Hollander P, Lewin A, Gabbay rA, Hu P, 
Bode B, Garber A; iNiTiATe Study Group. initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265.35 
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One of the benefits of premixed insulin analogue therapy 
is the ease with which treatment can be intensified. Because 
of the rapid-acting nature of the soluble component of 
BIAsp 30 (aspart), it can be injected three-times daily (tid) 
if required.45,47,50 This means that an addition or change in 
insulin is not required when intensifying from an od or bid 
regimen. Convenience thus extends to the injection device – 
patients can continue to use the same injection device, the 
FlexPen® (Novo Nordisk A/S, Denmark), for all injections, 
eliminating the possibility of mixing up insulins.54–56
Several studies have assessed the efficacy of od, bid and 
tid regimens of BIAsp 30 in patients with type 2 diabetes. 
In general, more injections enable more patients to reach 
glycemic targets. The 1–2–3 trial by Garber et al50 in 
patients previously treated with OADs only or OADs plus 
basal insulin od, started 100 patients on BIAsp 30 od, and 
transferred all patients who did not achieve HbA1c  6.5% 
after 16 weeks to BIAsp 30 bid, and then to tid after a 
further 16 weeks if this target was not met. Cumulatively, 
by the end of the three treatment periods, od, bid and tid 
BIAsp 30 enabled 40%, 70% and 77% of patients to achieve 
HbA1c  7.0%.50 Similarly, a 24-week Chinese study found 
that monotherapy with BIAsp 30 tid got 65.8% of previously 
insulin-naive patients to HbA1c  7.0%, compared with 
51.3% with BIAsp 30 bid.47
However, a Russian trial has demonstrated that BIAsp 
30 bid plus metformin can be as efficacious as BIAsp 30 tid 
monotherapy. In this 16-week study of 308 insulin-naive 
patients, final HbA1c reductions were -3.0% and -2.9%, 
respectively. Indeed, it has recently been shown that BIAsp 
30 bid – even without concomitant OADs – can be almost as 
efficacious as basal-bolus therapy.44 Here, patients previously 
on OADs, with or without basal insulin od, were randomized 
to BIAsp 30 bid or insulin aspart tid (at mealtimes) plus basal 
analog insulin detemir od (or bid if required). After 6 months 
of therapy, HbA1c was reduced by -1.23% in the BIAsp 30 
arm and by -1.56% in the aspart/detemir arm (p = 0.0052), 
with 50% and 60% of patients reaching HbA1c  7.0%, 
respectively. Ninety-minute postprandial blood glucose 
levels after all three meals were also significantly lower 
with aspart/detemir. Interestingly, insulin-naive patients had 
greater HbA1c reductions than prior insulin-users, and there 
was no significant treatment difference in this subgroup.44 
These data suggest that starting insulin therapy with BIAsp 
30 bid can be just as beneficial as starting with basal insulin 
and intensifying to basal-bolus therapy, with the advantage 
of fewer daily injections in the long-term.
Safety profile and tolerability 
of BIAsp 30
Type 1 diabetes
Because of the relatively few studies of BIAsp 30 in patients 
with type 1 diabetes, hypoglycemia is the only adverse 
event reported in any detail. However, antibodies to insulin 
aspart – the insulin present in BIAsp 30 – have been measured 
in patients with type 1 and type 2 diabetes,57,58 but these were 
mostly not specific and cross-reactive with human insulin.57 
The antibody levels decreased after 3 months of aspart therapy 
and were not linked to glycemic control, so this should not be 
an issue for most patients starting BIAsp 30 therapy.
Hypoglycemia
The occurrence of major hypoglycemia varied between 
studies, and does not appear to be related to trial duration. 
The single-injection crossover study by Hermansen et al33 
described earlier, reported no major hypoglycemia in 
50 patients, while 14 of the 20 major episodes (defined as 
requiring third-party assistance) reported with BIAsp 30 bid 
therapy over 12 weeks were in type 1 patients (corresponding 
figures were 30 of 42 episodes for BHI 30).34 However, 
in the 24-week crossover study by Chen et al,32 a total of 
3 major events were reported by two patients with BIAsp 
30 tid (1 event was reported by 1 patient in the human insulin 
basal-bolus group). In adolescent patients, a total of 15 major 
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Figure 3 Significantly greater reduction in HbA1c after 12 weeks’ treatment with BiAsp 
30 plus metformin than with BHi 30 plus metformin in obese patients with type 2 dia-
betes. errors are SDs. reproduced with permission from  Velojic-Golubovic M,  Mikic D, 
Pesic M, Dimic D, radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic 
control than with premixed human insulin 30 in obese patients with type 2 diabetes. 
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episodes were reported over 16 weeks – 7 in the BIAsp 30 
tid group (from 6 of 86 patients) and 8 in the human insulin 
bid/BHI 30 od group (3 of 87 patients).31
Minor hypoglycemia is more frequent than major. Due 
to the different ways minor hypoglycemia has been reported, 
it is difficult to draw straight comparisons. In the 12-week 
trial by Boehm et al34 54% of patients reported minor events 
with BIAsp 30 bid (56% with BHI 30), while the incidence 
was 81% in adolescent patients over 16 weeks with BIAsp 
30 tid.31 Other studies reported event rate. Chen et al reported 
1.1 events per patient per week for all hypoglycemia (not 
just minor) with BIAsp 30 tid over 12 weeks, which rose to 
1.2 events per patient per week for those who added NPH 
insulin od to the regimen (compared with 0.7 events per patient 
per week for human insulin basal-bolus therapy).32 During the 
single-injection crossover study by Hermansen et al33 16 minor 
events were reported in 50 patients (18 events with BHI 30). 
Although comparisons between studies are difficult, it is clear 
that the incidence and rate of minor hypoglycemia is similar 
for BIAsp 30 and human insulin regimens.
weight gain
Weight gain is often not reported in studies of type 1 diabetes, 
possibly because many patients are relatively young and 
growing, so it is not perceived as a problem.
Type 2 diabetes
Adverse events
Adverse events (AEs) associated with BIAsp 30 in patients 
with type 2 diabetes were commonly reported in RCTs but 
often not described, with incidence ranging from 20%48 to 
76%36 of patients. Other than hypoglycemia, reported AEs 
with BIAsp 30 include peripheral edema (in 0%–9% of 
patients),37,48 infections and infestations (29 of 204 patients 
treated with BIAsp 30),45 neurological disorders (13 of 204 
patients),45 gastrointestinal disorders (8 of 204 patients),45 
upper respiratory tract infections (13%–21% of exposed 
patients),48 and headache (4%–10%).48
Hypoglycemia
Compared with type 1 diabetes, major hypoglycemia seems 
to be less frequent in type 2 diabetes. Indeed, several studies 
described in the efficacy section report no major hypogly-
cemia at all for BIAsp 30 or the comparator.40,44,45,48 In those 
trials that do report major hypoglycemia, the frequency varies 
from one event associated with BIAsp 30 therapy (od or 
bid39,42) to 4 events in 102 patients.37 In the 2-year study by 
Boehm et al, 3 patients (5%) on BIAsp 30 bid reported at 
least one major hypoglycemic event in the first year, but no 
events were reported during the second year.49
Minor hypoglycemia is certainly more frequent, but rates 
are still relatively low in some studies. In the Russian trial by 
Ushakova et al45 the minor hypoglycemia rate was only 0.73 
events per patient-year for BIAsp 30 tid or 0.69 events per 
patient-year for BIAsp 30 bid plus metformin (no statistical 
difference). This is lower than the 8.3 events per patient-year 
reported by Raskin et al37 for BIAsp 30 bid plus metformin and 
pioglitazone, but still does not seem to be a problematic level. At 
the higher end of the scale, the incidence of minor hypoglycemia 
reported in the PREFER study was 28% for BIAsp 30 bid,44 
compared with 31% for basal-bolus therapy, but 42% for BIAsp 
30 bid plus metformin, compared with 14% for insulin glargine 
in another study.36 This may be the result of dose optimization via 
aggressive titration, since these were treat-to-target studies.
Possibly the most feared by patients is nocturnal 
hypoglycemia because it can occur during sleep. Although 
several trials do report the occurrence of nocturnal hypoglycemia 
with BIAsp 30 therapy (Liebl et al44 give an incidence of 7.4% 
for bid dosing over 6 months), its frequency was lower – and 
significantly so – in two studies.34,51 Continuous interstitial 
glucose monitoring over 24 hours, as well as self-monitoring 
of blood glucose were used by McNally et al to identify the 
rate of diurnal and nocturnal hypoglycemia.51 The results 
indicated that nocturnal hypoglycemia (or low interstitial 
glucose, 3.5 mmol/L) went largely undetected by patients, 
and self-reported nocturnal hypoglycemia was significantly 
less frequent with BIAsp 30 bid than with BHI 30 bid (1.5 vs 
3.8 episodes/patient/year; p = 0.002).
weight gain
Because many patients with type 2 diabetes are overweight, 
weight gain associated with insulin therapy may be a barrier 
to initiating or intensifying insulin treatment. In the trials 
mentioned in this review, weight gain is frequently reported 
with insulin treatment, including BIAsp 30. For BIAsp od, 
reported weight gain ranges from 0.7 (with metformin40) 
to 5.2 kg (monotherapy41). In bid or tid regimens (with or 
without OADs), weight gain follows a similar range: 0.7 to 
5.4 kg.35,37–39,44 It seems sensible, therefore, that in cases where 
additional weight gain may pose further potential health 
problems, dietary and lifestyle advice given at the initiation of 
insulin therapy should be followed-up on a regular basis.
Observational studies
The results from RCTs described above have been confirmed in 
real-life patient populations by recent observational studies.7,59–65 Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 69
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These studies have been carried out in patients with type 2 
diabetes – there do not appear to be equivalent studies in type 1 
patients. Such studies are a valuable addition to RCTs because 
it is helpful for physicians to know that the results obtained in 
selected patients also apply to a broader population.66
In the relatively small (n = 500) observational study 
carried out in Denmark,59 and in two much larger, interna-
tional studies: PRESENT62–65 and IMPROVE™,7,59–61 HbA1c 
levels have been significantly reduced from baseline over 26 
weeks of BIAsp 30 therapy. Moreover, this has been reported 
not only in the overall cohorts, but also in previously insulin-
naive patients, those switching from other insulins (including 
basal insulins and human premix), and patients who had 
previously received no pharmaceutical therapy.59–62,64 In the 
largest of these studies, the IMPROVE™ study, which has 
reported a global cohort of 52,419 patients, the overall change 
in HbA1c at end-of-study with BIAsp 30 therapy was -2.3%, 
with the largest reduction observed in the ‘no pharmaceutical 
therapy’ subgroup (-3.1%), followed by those that were on 
OADs only prestudy (-2.1%) and insulin ± OADs prestudy 
(-2.0%). Also, as was often demonstrated in RCTs, fasting 
and postprandial blood glucose were significantly reduced 
from baseline in all prestudy therapy subgroups.60
Importantly, the IMPROVE™ study has provided useful 
information for physicians on how doses were adjusted when 
patients were transferred from other insulins to BIAsp 30. 
Patients who switched from human premix (BHI 30) achieved 
a lower final HbA1c when they transferred their dose to 
BIAsp 30 unit-for-unit, rather than to a higher or lower dose 
(more than 10% change in dose); moreover, more patients 
who switched unit-for-unit reached HbA1c  7.0% (43.7% 
vs 32.2% vs 38.5%, respectively).61 It is noteworthy that 
those patients who switched to a lower or higher dose also 
achieved significant reductions from baseline in all glycemic 
parameters. When patients were transferred from a basal insu-
lin to BIAsp 30 in the IMPROVE™ study, the prestudy dose 
was increased by about 50% at transfer (0.28 to 0.43 U/kg), 
with a small dose increase during the 26-week observation 
period (dose at final visit: 0.49 U/kg).67
The large numbers of patients recruited in some observational 
studies allow them to accurately report the number and diver-
sity of AEs, including hypoglycemia (within the limitations 
inherent in observational studies, such as patient recall bias). 
In the IMPROVE™ study, only 98 patients (0.19%) reported 
serious adverse drug reactions (SADRs), and most of these 
were hypoglycemia. The prevalence of all other SADRs (drug 
hypersensitivity, injection site reaction, rash) were less than 
0.005%.60
Hypoglycemia data from observational studies are more 
encouraging than one would expect, given the data reported 
in RCTs. For example, in RCTs minor hypoglycemia with 
BIAsp 30 is generally more frequent,35,38,40 or at best, similar 
to that with other insulins.39,49,51 In the PRESENT observa-
tional study, patients previously treated with insulin (with 
or without OAD combination therapy) reported significantly 
lower minor hypoglycemia 6 months after switching to BIAsp 
30 in routine care (from approximately 9.0 to 2.3 events 
per patient-year).62 Similar results were reported in the 
IMPROVE™ study.60 The incidence of major hypoglycemia 
in BIAsp 30 observational studies was very low, consistent 
with results from RCTs.35,38,49,51,60,62
The weight gain associated with insulin therapy that has 
frequently been reported in RCTs is another issue that has not 
been confirmed in the wider type 2 diabetes population.35,41,44,50 
Somewhat surprisingly, patients in the IMPROVE™ and 
PRESENT studies showed a small weight loss after 6 months 
therapy with BIAsp 30 (–0.1 and –0.32 kg, respectively, both 
p  0.001).60,62 It has been suggested that dietary advice given 
by their physicians during the observation period may have 
led to healthier eating habits among patients, which may have 
off-set any potential weight gain due to insulin therapy.60 
Whatever the reason, these large scale data are very encourag-
ing, particularly for those patients who are in need of insulin 
therapy, but are worried about weight gain.
Conclusion
BIAsp 30 has pharmacological properties that make it a viable 
choice for initiating, or intensifying, insulin therapy in patients 
with type 1 or type 2 diabetes. These include a rapid-acting 
prandial component which is absorbed quickly and reaches 
higher plasma concentrations than does human insulin, and a 
basal component which addresses fasting insulin needs. While 
HbA1c levels with BIAsp 30 in patients with type 1 diabetes are 
similar to those with human insulins, a benefit with regard to 
postprandial hyperglycemia has been demonstrated for BIAsp 
30 in RCTs. Compared with basal insulins, BIAsp 30 lowers 
HbA1c to a greater degree in patients with type 2 diabetes 
and again is particularly effective at reducing postprandial 
plasma glucose. While some RCTs report an increase in minor 
hypoglycemia with BIAsp 30 relative to basal insulin, major 
and nocturnal hypoglycemia are reportedly low. Furthermore, 
large-scale observational data support the findings from 
RCTs in type 2 patients. With the convenience of once- to 
three-times daily dosing with the same injection device – the 
FlexPen® – BIAsp 30 represents a simple and effective tool 
for the modern management of diabetes.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 70
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